Skip to main content

Advertisement

Table 1 TKI launched on market

From: Advances in studies of tyrosine kinase inhibitors and their acquired resistance

TKI Time to market Development company Target Application of disease
Imatinib 2001 Novartis Abl, PDGFR, SCFR CML, GIST
Gefitinib 2003 AstraZeneca EGFR NSCLC
Nilotinib 2004 Novartis Bcr-Abl, PDGFR CML
Sorafenib 2005 Bayer Raf, VEGFR, PDGER Advanced RCC
Sunitinib 2006 Pfizer PDGFR, VEGFR, GIST, Advanced RCC
Dasatinib 2006 Bristol-Myers Squibb Bcr-Abl, SRC, PDGFR CML
Lapatinib 2007 GlaxoSmithKline EGFR Breast cancer
Pazopanib 2009 GlaxoSmithKline VEGFR, PDGFR, FGFR Advanced RCC,STS,NSCLC
Crizotinib 2011 Pfizer ALK NSCLC
Ruxolitinib 2011 Novartis JAK1, JAK2 myelofibrosis
vandetanib 2011 AstraZeneca VEGFR, EGFR Advanced Thyroid cancer
Axitinib 2012 Pfizer VEGFR Advanced RCC
Bosutinib 2012 Wyeth Abl, SRC CML
Afatinib 2013 Boehringer Ingelheim EGFR NSCLC
Erlotinib 2013 Roche EGFR NSCLC
Ceritinib 2014 Novartis ALK NSCLC
Osimertinib 2015 AstraZeneca EGFR NSCLC
Lenvatinib 2015 Eisai VEGFR DTC
Alectinib 2015 Roche ALK NSCLC
Regorafenib 2017 Bayer VEGFR, EGFR HCC, CRC,GIST
Neratinib 2017 Puma HER2 Breast cancer
Brigatinib 2017 Ariad ALK NSCLC